AFT Pharmaceuticals Ltd. 2024 AR2
The report highlights AFT Pharmaceuticals' operational and financial performance for the fiscal year ended March 31, 2024, achieving record revenue of $195.4 million and EBITDA of $26.2 million. The company expanded its global footprint by launching products in 12 new countries and establishing new business hubs in the UK, Canada, and the US. Notably, AFT launched Maxigesic IV in the US and advanced its research and development pipeline to seven projects. On the sustainability front, the company completed its first climate risk assessment and released its inaugural disclosure in compliance with the Aotearoa New Zealand Climate Standards, establishing science-aligned targets for Scope 1 and 2 emissions.
Company: AFT Pharmaceuticals Ltd.
Sector: Manufacturing
Country: New Zealand
Year: 2024
Type: AR2
Pages: 126
Back to company
AFT Pharmaceuticals Ltd.
Annual Report
The report highlights AFT Pharmaceuticals' operational and financial performance for the fiscal year ended March 31, 2024, achieving record revenue of $195.4 million and EBITDA of $26.2 million. The company expanded its global footprint by launching products in 12 new countries and establishing new business hubs in the UK, Canada, and the US. Notably, AFT launched Maxigesic IV in the US and advanced its research and development pipeline to seven projects. On the sustainability front, the company completed its first climate risk assessment and released its inaugural disclosure in compliance with the Aotearoa New Zealand Climate Standards, establishing science-aligned targets for Scope 1 and 2 emissions.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Apr 1, 2023 - Mar 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees